Evaluation of the association between blood homocysteine concentration and the degree of behavioral symptoms in the 6-hydroxydopamine-induced Parkinsonism in rat
“…Therefore, antiparkinsonian and neuroprotective effects of B com were probably mediated by reduction of oxidative stress. It was in agreement with several data showing that B vitamins had antioxidant effects (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34).…”
Section: Discussionsupporting
confidence: 92%
“…tion of mitochondrial dysfunction and inhibition of oxidative stress (22). Previously, it was shown that B vitamins can reduce severity of behavioral symptoms in 6-hydroxydopamine (6-OHDA)-induced model of Parkinson disease (23,24).…”
Background: The current study evaluated the effects of a combination of flunarizine (flu) a calcium channel blocker, glibenclamide (Glib), a KATP channels blocker and B vitamins (B com) on the behavioral symptoms of 6-hydroxydopamine (6-OHDA)-induced model of Parkinson disease to examine the synergistic antiparkinsonian effects of the drugs and supplements. Also the level of malondialdehyde (MDA) was measured in blood and brain suspensions to find probable neuroprotective mechanism of these materials.
“…Therefore, antiparkinsonian and neuroprotective effects of B com were probably mediated by reduction of oxidative stress. It was in agreement with several data showing that B vitamins had antioxidant effects (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34).…”
Section: Discussionsupporting
confidence: 92%
“…tion of mitochondrial dysfunction and inhibition of oxidative stress (22). Previously, it was shown that B vitamins can reduce severity of behavioral symptoms in 6-hydroxydopamine (6-OHDA)-induced model of Parkinson disease (23,24).…”
Background: The current study evaluated the effects of a combination of flunarizine (flu) a calcium channel blocker, glibenclamide (Glib), a KATP channels blocker and B vitamins (B com) on the behavioral symptoms of 6-hydroxydopamine (6-OHDA)-induced model of Parkinson disease to examine the synergistic antiparkinsonian effects of the drugs and supplements. Also the level of malondialdehyde (MDA) was measured in blood and brain suspensions to find probable neuroprotective mechanism of these materials.
“…Behavioral assessment using the forelimb akinesia test showed that rats injected with 6-OHDA had a longer average step length for the limb contralateral to the lesioned hemisphere. Studies have shown that neurotoxininduced degeneration of dopamine neurons leads to motor deficit development that can be quantified using behavioral tests (Santiago et al, 2010;Haghdoost-Yazdi et al, 2014). The difficulty in movement initiation is a result of an increase in tonic inhibition of the neurons in the thalamocortical region of the brain (Warabi et al, 2011).…”
“…Hence, this enzyme can relieve the inhibitory activities of SAH on S-adenosyl methionine (SAM)-dependent transmethylation reactions [17,18]. However, dysfunctional AHCY activity can result in serious pathological consequences, such as childhood death [19], Alzheimer' s disease [20], Parkinson' s disease [21], age-related diseases [22], neuroblastoma [23], and large-artery atherosclerotic stroke [24]. Despite these negative outcomes, few studies have investigated the relationship between AHCY DNA methylation of AHCY may increase the risk of ischemic stroke www.bjbms.org and the risk of ischemic stroke.…”
Genetic factors play an important role in the pathogenesis of ischemic stroke. Of these, epigenetic modifications provide a new direction for the study of ischemic stroke pathogenesis. This study aimed to determine the correlation between DNA methylation of the gene encoding S-adenosylhomocysteine hydrolase (AHCY) and the risk of ischemic stroke in 64 ischemic stroke patients and 138 patients with traumatic brain injury (control group). The methylation level of AHCY was analyzed using quantitative methylation-specific polymerase chain reaction. Statistically significant differences in AHCY methylation levels were observed between the case group [medians (interquartile range): 0.13% (0.09%, 0.27%)] and the control group [0.06% (0.00%, 0.17%), p < 0.0001], and these associations remained significant in both male (p = 0.003) and female (p = 0.0005) subjects. A subgroup analysis by age revealed a considerably higher percentage of methylated AHCY in the case group than the control group in all age groups (age < 60 years, p = 0.007; age ≥ 60 years, p < 0.0001). A receiver operating characteristic (ROC) curve analysis revealed a trend toward a role for AHCY methylation as an indicator of risk in all ischemic patients [area under the curve (AUC) = 0.70, p = 0.0001], male patients (AUC = 0.67, p = 0.004), and female patients (AUC = 0.75, p = 0.0002). Our study confirmed a significant association between the AHCY DNA methylation level and the risk of ischemic stroke, suggesting that this gene methylation pattern may be a potential diagnostic marker of ischemic stroke.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.